InsidersTradesSigma
Follow the 리메드 share price and the full insider trade history of the company, a listed equity based in South Korea. Shares trade on the KR market, under the oversight of DART (FSS). Operating in the Health Care sector, 리메드 has logged 77 reports. Market capitalisation: €85.4bn. The latest transaction was reported on 24 June 2026 (Other). Among the most active insiders: 이근용. Every trade is accessible without an account.
76
Insider Decl.
n/a
Thresholds
n/a
8 ops.
Buy Volume
n/a
2 ops.
Sell Volume
Fundamental score
Ranked 20,589 of 29,056 companies
37.8
score / 100
Value30
Quality46
FCF yld1.8%
Earn yld0.6%
EV/EBITDA44.3x
ROE1.8%
Gross mgn57%
Net mgn2.1%
Debt/EBITDA2.7x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 24 June 2026
Declarations77 total
Other
576,725 sharesKRXDART:20250903000264
25 of 77 declarations
关于 리메드
리메드 活跃于医疗保健和制药领域，在 XKRX 市场上市。该公司专注于开发创新的解决方案以改善医疗保健。